These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 9625577)

  • 1. Efficacy and safety of continuous infusion of Mononine during five surgical procedures in three hemophilic patients.
    Ménart C; Petit PY; Attali O; Massignon D; Dechavanne M; Négrier C
    Am J Hematol; 1998 Jun; 58(2):110-6. PubMed ID: 9625577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Continuous intravenous infusion of a plasma-derived factor IX concentrate (Mononine) in haemophilia B.
    Hoots WK; Leissinger C; Stabler S; Schwartz BA; White G; Dasani H; Massion C; Negrier C; Schindel F; Schulman S
    Haemophilia; 2003 Mar; 9(2):164-72. PubMed ID: 12614367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Variability of in vivo recovery of factor IX after infusion of monoclonal antibody purified factor IX concentrates in patients with hemophilia B. The Mononine Study Group.
    White GC; Shapiro AD; Kurczynski EM; Kim HC; Bergman GE
    Thromb Haemost; 1995 May; 73(5):779-84. PubMed ID: 7482403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates.
    Roth DA; Kessler CM; Pasi KJ; Rup B; Courter SG; Tubridy KL;
    Blood; 2001 Dec; 98(13):3600-6. PubMed ID: 11739163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of a recombinant factor IX (Bax326) in previously treated patients with severe or moderately severe haemophilia B undergoing surgical or other invasive procedures: a prospective, open-label, uncontrolled, multicentre, phase III study.
    Windyga J; Lissitchkov T; Stasyshyn O; Mamonov V; Ghandehari H; Chapman M; Fritsch S; Wong WY; Pavlova BG; Abbuehl BE
    Haemophilia; 2014 Sep; 20(5):651-8. PubMed ID: 24697870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and recovery of mononine in multiple-dose, high-dose regimens.
    White GC
    Acta Haematol; 1995; 94 Suppl 1():53-7; discussion 57-8. PubMed ID: 7571996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Purified factor IX using monoclonal immunoaffinity technique: clinical trials in hemophilia B and comparison to prothrombin complex concentrates.
    Kim HC; McMillan CW; White GC; Bergman GE; Horton MW; Saidi P
    Blood; 1992 Feb; 79(3):568-75. PubMed ID: 1531035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coronary artery bypass grafting in a patient with hemophilia B: continuous recombinant factor IX infusion as per the Japanese guidelines for replacement therapy.
    Suzuki T; Kawamoto S; Kumagai K; Adachi O; Kanda K; Ishikawa M; Okitsu Y; Harigae H; Kurosawa S; Saiki Y
    Gen Thorac Cardiovasc Surg; 2016 Aug; 64(8):481-3. PubMed ID: 25523881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of continuous infusion of factor concentrates in the treatment of hemophilia.
    Bona RD; Weinstein RA; Weisman SJ; Bartolomeo A; Rickles FR
    Am J Hematol; 1989 Sep; 32(1):8-13. PubMed ID: 2502914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 3 Clinical Trial: Perioperative Use of Nonacog Gamma, a Recombinant Factor IX, in Previously Treated Patients With Moderate/Severe Hemophilia B.
    Windyga J; Timofeeva M; Stasyshyn O; Mamonov V; Lamas Castellanos JL; Lissitchkov T; Chojnowski K; Chapman M; Pavlova BG; Tangada S
    Clin Appl Thromb Hemost; 2020; 26():1076029620946839. PubMed ID: 32816519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical evaluation of recombinant factor IX.
    White G; Shapiro A; Ragni M; Garzone P; Goodfellow J; Tubridy K; Courter S
    Semin Hematol; 1998 Apr; 35(2 Suppl 2):33-8. PubMed ID: 9565165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Secondary prophylaxis with factor IX concentrates: continuous infusion.
    Morfini M
    Blood Transfus; 2008 Sep; 6 Suppl 2(Suppl 2):s21-5. PubMed ID: 19105506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B.
    Powell JS; Pasi KJ; Ragni MV; Ozelo MC; Valentino LA; Mahlangu JN; Josephson NC; Perry D; Manco-Johnson MJ; Apte S; Baker RI; Chan GC; Novitzky N; Wong RS; Krassova S; Allen G; Jiang H; Innes A; Li S; Cristiano LM; Goyal J; Sommer JM; Dumont JA; Nugent K; Vigliani G; Brennan A; Luk A; Pierce GF;
    N Engl J Med; 2013 Dec; 369(24):2313-23. PubMed ID: 24304002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of long-acting recombinant fusion protein linking factor IX with albumin in haemophilia B patients undergoing surgery.
    Négrier C; Abdul Karim F; Lepatan LM; Lienhart A; López-Fernández MF; Mahlangu J; Pabinger I; Li Y; Wolko D; Voigt C; Jacobs I; Santagostino E
    Haemophilia; 2016 Jul; 22(4):e259-66. PubMed ID: 27333467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of a high purity, chemically treated and nanofiltered factor IX concentrate for continuous infusion in haemophilia patients undergoing surgery.
    Schulman S; Wallensten R; White B; Smith OP
    Haemophilia; 1999 Mar; 5(2):96-100. PubMed ID: 10215956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of investigator-prescribed BeneFIX prophylaxis in children less than 6 years of age with severe haemophilia B.
    Monahan PE; Liesner R; Sullivan ST; Ramirez ME; Kelly P; Roth DA
    Haemophilia; 2010 May; 16(3):460-8. PubMed ID: 20059559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant factor IX for the treatment of hemophilia B. Introduction.
    Thompson A
    Semin Hematol; 1998 Apr; 35(2 Suppl 2):1-3. PubMed ID: 9565159
    [No Abstract]   [Full Text] [Related]  

  • 18. Long-acting recombinant factor IX Fc fusion protein (rFIXFc) for perioperative management of subjects with haemophilia B in the phase 3 B-LONG study.
    Powell JS; Apte S; Chambost H; Hermans C; Jackson S; Josephson NC; Mahlangu JN; Ozelo MC; Peerlinck K; Pasi J; Perry D; Ragni MV; Wang X; Jiang H; Li S; Cristiano LM; Innes A; Nugent K; Brennan A; Luk A; Allen G; Pierce GF; Robinson B
    Br J Haematol; 2015 Jan; 168(1):124-34. PubMed ID: 25208598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-factor consumption for major surgery in haemophilia B with long-acting recombinant glycoPEGylated factor IX.
    Escobar MA; Tehranchi R; Karim FA; Caliskan U; Chowdary P; Colberg T; Giangrande P; Giermasz A; Mancuso ME; Serban M; Tsay W; Mahlangu JN
    Haemophilia; 2017 Jan; 23(1):67-76. PubMed ID: 27480487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics, safety and efficacy of a recombinant factor IX product, trenonacog alfa in previously treated haemophilia B patients.
    Collins PW; Quon DVK; Makris M; Chowdary P; Kempton CL; Apte SJ; Ramanan MV; Hay CRM; Drobic B; Hua Y; Babinchak TJ; Gomperts ED
    Haemophilia; 2018 Jan; 24(1):104-112. PubMed ID: 28833808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.